2-[4-[6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-[4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile;2-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-(4-piperidin-1-ylbut-2-enoyl)piperazin-2-yl]acetonitrile(CAS: 25817-87-2)

The compound 2-[4-[6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-[4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (CAS: 25817-87-2) is subject to various regulatory guidelines. It must comply with the Chemicals in the European Union (REACH) regulations, which require registration, evaluation, authorization, and restriction of chemical substances. In the United States, it must adhere to the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) regulations, which include safety data sheets (SDS) and proper labeling. Additionally, it should be handled in accordance with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for chemical hazards.

There are alternative reagents and synthetic pathways that can be used in place of 2-[4-[6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-[4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (CAS: 25817-87-2) for synthesis. For instance, similar quinazolines with different substituents can be used. Additionally, alternative piperazine derivatives or different functional groups can be explored to achieve similar structural features. It is important to consider the availability, cost, and reactivity of these alternatives.

The market and research trends for 2-[4-[6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-[4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (CAS: 25817-87-2) are primarily driven by its potential applications in the pharmaceutical industry due to its unique chemical structure. Recent research trends include its use in drug discovery and development, particularly for treating inflammatory and neurodegenerative diseases. Market trends indicate an increasing demand for such specialized compounds, driven by ongoing clinical trials and patent expiration of older drugs.

Waste containing 2-[4-[6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methoxyquinazolin-4-yl]-1-[4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (CAS: 25817-87-2) should be managed according to the appropriate waste disposal regulations. Waste liquid should be collected in suitable containers, labeled with the chemical name and CAS number, and stored in a designated area. For solid waste, it should be encapsulated or neutralized if necessary, then disposed of through a hazardous waste management facility. Environmental protection precautions include ensuring no spillage and proper ventilation during handling. It is advisable to consult with environmental health and safety (EHS) professionals for specific disposal procedures.